跳至主要内容
临床试验/CTRI/2026/01/100110
CTRI/2026/01/100110尚未招募Phase 3 4

Efficacy and safety of Hydrocortisone in severe Pneumonia patients- A Randomized Controlled trial

DR Ashish Ranjan Sahoo and DR Srikant Behera1 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2026年1月30日最近更新:

试验速览

阶段
Phase 3 4
状态
尚未招募
发起方
入组人数
136
试验地点
1

研究概览

简要总结

My present study will evaluate efficacy and safety of Hydrocortisone in severe pneumonia patients in reducing mortality and duration of mechanical ventilation and hospital length of stay. Corticosteroid  has strong  physiological back ground for use in severe pneumonia to deal with dysregulated host response to infection There is no guideline for usage of hydrocortisone in severe pneumonia patients There is no study in indian population on Hydrocortisone treatment for severe pneumonia patients

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
14.00 Year(s) 至 95.00 Year(s)(—)
性别
All

入选标准

  • 1.Diagnosis of severe pneumonia as per ATS/IDSA guideline 2.consent to participate in study.

排除标准

  • 1 Patient was already on vasopressor therapy for septic shock at the time of inclusion 2 Diagnosed case of active tb herpes infection 3 History of preexisting structural lung disease on steroid dependent conditions 4 Hypersensitivity to corticosteroid 5 Known case of myelosuppression.

研究者

发起方
DR Ashish Ranjan Sahoo and DR Srikant Behera
申办方类型
Other [self funded for PG thesis]
责任方
Principal Investigator
主要研究者

DR Srikant Behera

AIIMS Bhubaneswar

研究点 (1)

Loading locations...

相似试验